$3.10
0.186.16%
At Close: -
$2.71
-0.39-12.58%
After Hours: 8:10 AM EDT
15 minutes delayed
SAB Biotherapeutics
SABSNASDAQ
SAB Biotherapeutics (NASDAQ:SABS) Stock, Earnings Estimates, EPS, And Revenue
SAB Biotherapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Aug 19
EPS Estimate
$-1.030
Quarterly Revenue Estimate
–
Annual Revenue
(as of Mar 31)
(as of Mar 31)
–
Analyze the earnings history of SAB Biotherapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics | -$1.40 | -$1.03 | — | — | $85.52K | — | — | — | 08/19/2024 | Get Alert |
| SABS | SAB Biotherapeutics | -$1.50 | -$0.46 | -$0.54 | -17.39% | $581.10K | — | $944.58K | — | 05/20/2024 | Get Alert |
| SABS | SAB Biotherapeutics | -$1.80 | -$0.62 | -$3.84 | -519.35% | $2.16M | — | $305.01K | — | 03/29/2024 | Get Alert |
| SABS | SAB Biotherapeutics | -$1.60 | -$1.20 | -$1.00 | 16.67% | $3.59M | $20.00K | $1.27M | 6235.00% | 11/13/2023 | Get Alert |
| SABS | SAB Biotherapeutics | -$1.10 | — | -$1.40 | — | $6.35M | — | $85.52K | — | 08/21/2023 | Get Alert |
| SABS | SAB Biotherapeutics | $0.20 | -$0.80 | -$1.50 | -87.50% | $11.80M | $2.36M | $581.10K | -75.38% | 05/16/2023 | Get Alert |
| SABS | SAB Biotherapeutics | — | -$0.30 | -$1.80 | -500.00% | — | $6.50M | $2.16M | -66.75% | 04/14/2023 | Get Alert |
| SABS | SAB Biotherapeutics | -$1.60 | -$1.60 | -$1.60 | 0.00% | $14.68M | $6.85M | $3.59M | -47.59% | 11/15/2022 | Get Alert |
| SABS | SAB Biotherapeutics | -$1.10 | — | -$1.10 | — | $18.21M | — | $6.35M | — | 08/10/2022 | Get Alert |
| SABS | SAB Biotherapeutics | $0.50 | — | $0.20 | — | $16.93M | — | $11.80M | — | 05/12/2022 | Get Alert |
SAB Biotherapeutics (SABS) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Mar 2024 | 2024-05-20 | $-0.54 | $-0.46 | -17.4 % |
| Dec 2023 | 2024-03-29 | $-3.84 | $-0.62 | -519.4 % |
| Sep 2023 | 2023-11-13 | $-1.00 | $-1.20 | 16.7 % |
| Mar 2023 | 2023-05-16 | $-1.50 | $-0.80 | -87.5 % |
SAB Biotherapeutics (SABS) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2023 | 2023-11-13 | $1.27M | $20.00K | 6235.0 % |
| Mar 2023 | 2023-05-16 | $581.10K | $2.36M | -75.4 % |
| Mar 2023 | 2023-04-14 | $2.16M | $6.50M | -66.8 % |
| Sep 2022 | 2022-11-15 | $3.59M | $6.85M | -47.6 % |
FAQ
When is SAB Biotherapeutics (NASDAQ:SABS) reporting earnings?
SAB Biotherapeutics (SABS) is scheduled to report earnings on August 19, 2024. The last reported earnings were for reported on May 20, 2024 for Q1.
What were the latest earnings per share (EPS) for SAB Biotherapeutics (NASDAQ:SABS)?
The Actual EPS was $-0.54, which missed the estimate of $-0.46.
What were SAB Biotherapeutics’s (NASDAQ:SABS) revenues?
The Actual Revenue was $944.6K, which beat the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.